Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Comparison of survival between de novo stage IV and recurrent stage IV gastric cancer.
Authors
Jun Ho Ji
Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea;
Jun Ho Ji , Danbi Lee , Yong-Pyo Lee , Seok Jae Huh , Se-Il Go , Jung Hoon Kim , Sung Yong Oh , Jung Hun Kang , Kwang Min Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 304)
DOI
10.1200/JCO.2023.41.4_suppl.304
Abstract #
304
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A scoring system for selecting nivolumab or irinotecan in the later-line chemotherapy for advanced gastric cancer: A Japanese multicenter retrospective study.
First Author: Yusuke Amanuma
First Author: Sylvie Lorenzen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
CA125 kinetics as a potential biomarker of prognosis in nivolumab monotherapy for patients with advanced gastric cancer and peritoneal metastasis.
First Author: Takayuki Ando